

Q3 2015 [VentureDeal](#) Quarterly Venture Capital Report

Biotechnology - Medical Devices - Pharmaceuticals

Life Science companies secured \$3.4 billion in venture capital financing during Q3 2015, representing a decrease of 8% versus the previous quarter. The funding was allocated between 213 companies, a 3% decrease versus the previous quarter.


Biotechnology

Biotechnology funding was down from the previous quarter, decreasing by 12% during the quarter. The number of companies funded also decreased, by 9% versus the previous quarter.

[Stemcentrx](#) raised \$250 million in late stage venture equity capital to continue development of medicines to significantly improve survival rates for cancer patients by eliminating cancer stem cells which initiate and perpetuate tumors. Investors included Peter Thiel's [Founders Fund](#) and [Fidelity Management & Research Company](#).

Gene editing technology company [Editas](#) landed \$120 million from a syndicate of private equity and other investors, according to a company statement. Editas said it would use the proceeds to develop broadly its genome editing platform in advance multiple new therapies toward clinical trials.

Biotechnology Funding History - to 3rd Quarter 2015




Pharmaceuticals

Pharmaceutical fundings decreased to \$846 million, representing a 6% decrease in amounts funded but a 21% increase in the number of companies funded.

New York-based [Turing Pharmaceuticals](#) secured \$90 million in venture equity and debt capital from investors. The company says that it is a “fully integrated biopharmaceutical company focusing on patients with unmet medical needs.” Specific proceeds purposes from the financing were not disclosed.

Cambridge, Massachusetts-based Checkmate Pharmaceuticals raised \$20 million in Series A equity capital from venture capital investors led by [Sofinnova Ventures](#). Checkmate will use the funding proceeds to develop additional generations of oligonucleotide-based products in the field of immuno-oncology.

Pharmaceuticals Funding History - to 3rd Quarter 2015



Medical Devices

Venture capital funding for Medical Device companies remained flat in total amounts funded, at \$1.1 billion. The number of companies funded dropped from 91 to 86.

The largest funding event during the quarter was \$200 million in venture equity from a large syndicate of venture capital investors for Littleton, Massachusetts-based [Mevion Medical Systems](#). The company said it would use the proceeds to launch its joint venture in China to “produce, sell and service proton therapy systems for the Chinese market.”

Medical Devices Funding History - to 3rd Quarter 2015




Table 1
Venture Capital Funding - 3rd Quarter 2015

Industry	Total Disclosed Funding	% Change Vs. Prior Quarter	Number of Companies Funded	% Change vs. Prior Quarter
Biotechnology	\$1.5 billion	- 12 %	86	- 9 %
Pharmaceuticals	\$846 million	- 6 %	41	+ 21 %
Medical Devices	\$1.1 billion	-- %	86	- 5%
Total	\$3.4 billion	- 8 %	213	- 3 %

This material has been prepared and issued by VentureDeal. The information contained herein is based on current information that VentureDeal considers reliable, but we make no representation that it is accurate in the future or complete, and it should not be relied upon as such. It is provided with the understanding that VentureDeal is not acting in a fiduciary capacity.